Pharmacokinetics, Safety, and Tolerability Study of GOPRELTO® Nasal Solution
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Pharmaceutical Project Solutions, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04792034
PK Study of Intranasal RX0041-002 in Subjects With Severe Renal Impairment and Normal Renal Function
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: RX0041
- First Posted Date
- 2016-05-18
- Last Posted Date
- 2018-04-06
- Lead Sponsor
- Pharmaceutical Project Solutions, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02775955
- Locations
- 🇺🇸
Comprehensive Clinical Researc, Berlin, New Jersey, United States
Pharmacokinetic Study of Intranasal RX0041-002 in Hepatic-Impaired Individuals and Subjects With Normal Hepatic Function
- First Posted Date
- 2016-05-18
- Last Posted Date
- 2018-09-06
- Lead Sponsor
- Pharmaceutical Project Solutions, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02775981
- Locations
- 🇺🇸
Comprehensive Clinical Researc, Berlin, New Jersey, United States
Phase I Pharmacokinetic Study of RX0041-2
Phase 1
Completed
- Conditions
- Drug Reaction to Analgesic Nos
- Interventions
- Drug: RX0041-2
- First Posted Date
- 2016-01-28
- Last Posted Date
- 2016-01-28
- Lead Sponsor
- Pharmaceutical Project Solutions, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT02667106
Topical Anesthetic for Procedures Through the Nose
Phase 3
Completed
- Conditions
- Drug Reaction to Analgesic Nos
- Interventions
- Drug: RX0041 4%Drug: PlaceboDrug: RX0041 8%
- First Posted Date
- 2016-01-28
- Last Posted Date
- 2016-05-17
- Lead Sponsor
- Pharmaceutical Project Solutions, Inc.
- Target Recruit Count
- 648
- Registration Number
- NCT02667054
- Locations
- 🇺🇸
South Carolina ENT, Columbia, South Carolina, United States
🇺🇸Aroesty Advocare ENT, Mount Arlington, New Jersey, United States
© Copyright 2025. All Rights Reserved by MedPath